Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Fineline Cube Dec 30, 2025
Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Fineline Cube Dec 30, 2025
Company Deals Medical Device

Peijia Medical and DSM-Firmenich Collaborate on Polymer Heart Valve Innovation

Fineline Cube Apr 2, 2025

Peijia Medical Technology (Suzhou) Co., Ltd. today held a strategic innovation cooperation signing ceremony and...

Company Drug

Henlius and Organon’s HLX11 Biosimilar Clears EMA Validation Hurdle

Fineline Cube Apr 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Medicines...

Company Drug

Huadong Medicine’s Semaglutide Injection Accepted for Review by China’s NMPA

Fineline Cube Apr 2, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Medtronic Partners with Methinks AI to Enhance Stroke Care in Emerging Markets

Fineline Cube Apr 2, 2025

Medtronic announced a strategic partnership with Methinks AI, a leading provider of AI-driven radiological triage...

Company Drug

Hengrui Pharmaceuticals Secures Clinical Trial Approval for HRS-9813 in IPF

Fineline Cube Apr 2, 2025

Hengrui Pharmaceuticals (SHA: 600276) announced on April 1, 2025, that its HRS-9813 capsule has received...

Company Medical Device

Sino Medical Sciences Secures Malaysian Approval for Coronary Balloon Catheter

Fineline Cube Apr 1, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval in Malaysia...

Company Drug

Luye Pharma’s Weekly Rivastigmine Patch Approved in Japan for Alzheimer’s

Fineline Cube Apr 1, 2025

China-based Luye Pharma Group (HKG: 2186) announced that it has received marketing approval from Japan’s...

Company Drug

BeiGene’s Tevimbra Recommended for EU Approval in Small Cell Lung Cancer

Fineline Cube Apr 1, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist proposing to rename...

Company Drug

Otsuka Files FDA Application for Sibeprenlimab in IgAN Treatment

Fineline Cube Apr 1, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd. announced the filing of a Biologics License Application (BLA) with...

Company

Basecare Medical Reports 44% Revenue Growth in 2024 IVF Sector

Fineline Cube Apr 1, 2025

China-based IVF specialist Suzhou Basecare Medical Co., Ltd (HKG: 2170) has released its 2024 performance...

Company Drug

UCB’s Rystiggo Approved in China for Generalized Myasthenia Gravis

Fineline Cube Apr 1, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from China‘’s National...

Deals Hospital

Renji Hospital Partners with Raffles Medical Group to Boost Shanghai’s Medical Tourism

Fineline Cube Apr 1, 2025

Renji Hospital, a comprehensive Class 3A hospital established in 1844 in Shanghai, has partnered with...

Company Drug

AstraZeneca and Daiichi Sankyo Initiate DESTINY-Gastric05 Study for Enhertu in Metastatic Gastric Cancer

Fineline Cube Apr 1, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the first patient dosing in...

Medical Device Policy / Regulatory

China Proposes New Measures to Optimize High-End Medical Device Regulation

Fineline Cube Apr 1, 2025

The National Medical Products Administration (NMPA) has released the “Measures for Optimizing Full Lifecycle Supervision...

Company Deals

GE Healthcare Takes Full Ownership of Japan’s Nihon Medi-Physics

Fineline Cube Apr 1, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc., (NASDAQ: GEHC) announced that...

Company Drug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Rheumatoid Arthritis in China

Fineline Cube Apr 1, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Deals

Chinese Firms Nanjing F&S and Hunan Huize Form Alliance for Full-Process Pharma Services

Fineline Cube Apr 1, 2025

Chinese companies Nanjing F&S Pharmatech Co., Ltd and Hunan Huize Biopharmaceutical Technology Co., Ltd, a...

Company Drug

Huapont Life Sciences Gains NMPA Approval for Generic Daivobet

Fineline Cube Apr 1, 2025

China-based Huapont Life Sciences Co., Ltd (SHE: 002004) announced that it has received marketing approval...

Company Deals

Chinese IVD Firm Annoroad Gene Targets Global Expansion with IPO

Fineline Cube Apr 1, 2025

China-based Annoroad Gene Technology (Beijing) Co., Ltd. has submitted an initial public offering (IPO) filing...

Company Drug

Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study

Fineline Cube Apr 1, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...

Posts pagination

1 … 121 122 123 … 602

Recent updates

  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
  • TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.